DESIGN AND EVALUATION OF GUANFACINE EXTENDED RELEASE FORMULATION
Objective: The present study was aimed to develop of the Guanfacine Hydrochloride Extended-release tablets for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The dosage regimen of Guanfacine Hydrochloride is 4 mg at every 6 h. The concentration of Guanfacine in plasma is fluctuating. Hence, to control the plasma fluctuation and to avoid toxicity problem, Guanfacine Hydrochloride was chosen as a drug with an aim to develop an extended release system for 20 to 24 h.
Methods: The design of the system was based on the use of pH-dependent polymer (Hydroxypropyl Methyl Cellulose), pH-independent polymer (Eudragit L 100-55), along with microenvironment modifiers such as organic acid (Fumaric acid) were used in the formulation. Drug-excipient compatibility was studied by FTIR. Before compression, the granules were evaluated for precompression parameters such as bulk density, tapped density, an angle of repose, compressibility index and Hausner’s ratio. After compression, evaluation tests of tablets such as general appearance, hardness, thickness, weight variation, friability, content uniformity, in vitro release studies and stability studies were performed.
Results: Out of 9 formulations, the drug release was found to be within the innovator formulation F9. The stability study of formulation F9 revealed there was no significant change in physical and chemical properties of drug stored at 40 °C/75 % RH, 30 °C/65 % RH, 25 °C/60 % RH for 2 mo.
Conclusion: Optimized formulation batch F9 showed highest F2 value which indicates similarity with innovator product. The study indicates that Guanfacine Hydrochloride Extended-release tablet was successfully developed.
2. Chiao CL, Robinson JR. In: Remington: the science and practice of pharmacy. 19th Gennaro AR. Ed; Mack Publishing Company; 1995. p. 1660-70.
3. Lachman L, Liberman HA. Theory and practice of industrial pharmacy. 3rd Varghese publishing house: Mumbai; 1990. p. 314-24.
4. Desai SR, Disouza JI, Musle KL, Hosmani AH. Solubility enhancement of ritonavir by hot melt extrusion. Int J Pharm Pharm Sci 2016;8:309-12.
5. Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics a treatise. 1st Delhi: Vallabh Prakashan; 2002. p. 335-71.
6. Ochoa L, Igartua M. Novel extended release formulation of lovastatin by one-step granulation: in vitro and in vivo evaluation. Eur J Pharm Biopharm 2011;77:306-12.
7. Carla S, Sandra F. Didanosine extended-release matrix tablets: optimization of formulation variables using a statistical experimental design. Int J Pharm 2002;237:107-18.
8. Reddy SE. Formulation and evaluation of sustained release floating tablets of ciprofloxacin with hepatoprotectant. Int J Pharm Appl 2012;3:289-92.
9. Nagarajun R, Rajesh K. Design and evaluation of delayed and extended-release tablets of mesalamine. J Pharm Sci Tech 2010;2:103-10.
10. Desai SR, Disouza JI, Sable AM, Hosmani AH. Development of the orodispersible tablet of atorvastatin calcium using hot melt extrusion. Drug Delivery Lett 2015;5:1-12.
11. Higuchi T. Mechanism of sustained action mediation, theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963;52:1145-9.
12. Hixon AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem 1931;23:923-31.
13. Desai SR, Disouza JI, Shirwadkar BS. Process validation: an approach for herbal tablet standardization. Int J Pharmacogn Phytochem Res 2016;8:313-20.
14. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism of solute release from porous hydrophillic polymers. Int J Pharma 1983;15:25-35.
15. Desai SR, Doke AA, Disouza JI. Development and evaluation of antifungal topical niosomal gel formulation. Int J Pharm Pharm Sci 2011;3:224-31.
This work is licensed under a Creative Commons Attribution 4.0 International License.